WallStreetZenWallStreetZen

NASDAQ: NPCE
Neuropace Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NPCE

Based on 1 analyst offering 12 month price targets for Neuropace Inc.
Min Forecast
$6.00-23.95%
Avg Forecast
$6.00-23.95%
Max Forecast
$6.00-23.95%

Should I buy or sell NPCE stock?

Based on 1 analyst offering ratings for Neuropace Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NPCE stock forecasts and price targets.

NPCE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Morgan Stanley
Bottom 23%
23
HoldUpgrades$6.00-23.95%2023-08-24

1 of 1

Forecast return on equity

Is NPCE forecast to generate an efficient return?
Company
-208.33%
Industry
22.67%
Market
58.62%
NPCE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NPCE forecast to generate an efficient return on assets?
Company
-43.25%
Industry
11.73%
NPCE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NPCE revenue growth forecast

How is NPCE forecast to perform vs Medical Devices companies and vs the US market?
Company
10.07%
Industry
6.71%
Market
7.9%
NPCE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NPCE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NPCE vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
NPCE$7.89$6.00-23.95%Hold
AXGN$4.85$17.00+250.52%Strong Buy
TELA$8.07$15.00+85.87%Strong Buy
ALUR$4.95N/AN/A
MASS$6.04N/AN/A
View Top Medical Device Stocks

Neuropace Stock Forecast FAQ

Is Neuropace Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NPCE) stock is to Hold NPCE stock.

Out of 1 analyst, 0 (0%) are recommending NPCE as a Strong Buy, 0 (0%) are recommending NPCE as a Buy, 1 (100%) are recommending NPCE as a Hold, 0 (0%) are recommending NPCE as a Sell, and 0 (0%) are recommending NPCE as a Strong Sell.

If you're new to stock investing, here's how to buy Neuropace stock.

What is NPCE's forecast return on equity (ROE) for 2023-2025?

(NASDAQ: NPCE) forecast ROE is -208.33%, which is considered weak.

What is NPCE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NPCE price target, the average NPCE price target is $6.00, with the highest NPCE stock price forecast at $6.00 and the lowest NPCE stock price forecast at $6.00.

The Wall Street analyst predicted that Neuropace's share price could fall to $6.00 by Aug 24, 2024. The average Neuropace stock price prediction forecasts a potential downside of 23.95% from the current NPCE share price of $7.89.

What is NPCE's forecast return on assets (ROA) for 2023-2025?

(NASDAQ: NPCE) forecast ROA is -43.25%, which is lower than the forecast US Medical Devices industry average of 11.73%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.